Additionally, accumulating evidence demonstrated that the dysregulation of RUNX2 expression is frequently detectable in a variety of human cancers and higher expression level of RUNX2 is closely correlated with poor clinical outcome of the patients [122–124]. This evidence concerns the gene RUNX2 and cancer.